EUVIMEDEUVIMED entdecken
Open Access

Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy

Xiaojia Wang, Wei Li, Yongmei Yin, Zhongsheng Tong, Qingyuan Zhang, Hong Zheng, Zhimin Shao, Huiping Li, Jin Yang, Jifeng Feng, Fan Wu, Francois Lamour und 2 weitere

Translational Breast Cancer Research · 2023-01 · 4 · 3-3

DOI: 10.21037/tbcr-23-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Breast Cancer Research, 2023-01. Verfasst von Xiaojia Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

ELAINA bridging studyhuman epidermal growth factor receptor 2-positive (HER2-positive) breast cancermetastatic breast cancer (mBC)trastuzumab emtansine (T-DM1)

Autor:innen und Institutionen

  • Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
  • Department of Medical Oncology, The First Hospital of Jilin University, Changchun, China.
  • Department of Medical Oncology, Jiangsu Province Hospital, Nanjing, China.
  • Department of Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China.
  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Department of Medical Oncology, West China Hospital of Sichuan University, Chengdu, China.

ORCID-Profile: Zefei Jiang

Zitieren

APA

Wang, X., Li, W., Yin, Y., Tong, Z., Zhang, Q., Zheng, H., Shao, Z., Li, H., Yang, J., Feng, J., Wu, F., Lamour, F., Restuccia, E., & Jiang, Z. (2023). Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy. Translational Breast Cancer Research, 4, 3-3. https://doi.org/10.21037/tbcr-23-2

Vancouver

Wang X, Li W, Yin Y, Tong Z, Zhang Q, Zheng H, et al. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy. Translational Breast Cancer Research. 2023;4:3-3. doi:10.21037/tbcr-23-2

BibTeX
@article{Wang2023,
  author = {Wang, Xiaojia and Li, Wei and Yin, Yongmei and Tong, Zhongsheng and Zhang, Qingyuan and Zheng, Hong and Shao, Zhimin and Li, Huiping and Yang, Jin and Feng, Jifeng and Wu, Fan and Lamour, Francois and Restuccia, Eleonora and Jiang, Zefei},
  title = {Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy},
  journal = {Translational Breast Cancer Research},
  year = {2023},
  volume = {4},
  pages = {3--3},
  doi = {10.21037/tbcr-23-2}
}
Kostenlos starten →